Elkhayat H A, Aly R H, Elagouza I A, El-Kabarity R H, Galal Y I
Department of Pediatrics, Ain Shams University, Cairo, Egypt.
Department of Clinical Pathology, Ain Shams University, Cairo, Egypt.
Acta Neurol Scand. 2017 Dec;136(6):639-644. doi: 10.1111/ane.12778. Epub 2017 May 31.
The role of P-glycoprotein (Pgp), one of the known multidrug transporters, has been suggested in drug-resistant epilepsy (DRE). The following study aimed to measure the serum level of Pgp as a possible indicator of tissue Pgp overexpression in patients with DRE and to assess the efficacy of verapamil (as a Pgp inhibitor agent) in these patients.
A group of 24 patients with DRE were recruited and subdivided into two groups, one receiving verapamil and the other receiving a placebo in a double-blind randomized study. Pgp serum levels were measured at enrollment and 12 months later. Twenty medically controlled epileptic patients served as a control group.
A significant statistical increase was found in the Pgp level of patients when compared the control group. Patients on both verapamil and the placebo showed improvement in seizure frequency and severity where statistical analysis showed no significant differences.
Pgp serum levels in patients with DRE were significantly elevated compared to patients with medically controlled epilepsy. The effect of verapamil as Pgp inhibitor on DRE requires further evaluation and research.
已知的多药转运蛋白之一P-糖蛋白（Pgp）在耐药性癫痫（DRE）中的作用已被提出。以下研究旨在测量Pgp的血清水平，作为DRE患者组织中Pgp过表达的一个可能指标，并评估维拉帕米（作为一种Pgp抑制剂）对这些患者的疗效。
招募了一组24例DRE患者，并将其分为两组，在一项双盲随机研究中，一组接受维拉帕米治疗，另一组接受安慰剂治疗。在入组时和12个月后测量Pgp血清水平。20例药物控制良好的癫痫患者作为对照组。
与对照组相比，患者的Pgp水平有显著的统计学升高。服用维拉帕米和安慰剂的患者在癫痫发作频率和严重程度上均有改善，统计分析显示无显著差异。
与药物控制良好的癫痫患者相比，DRE患者的Pgp血清水平显著升高。维拉帕米作为Pgp抑制剂对DRE的作用需要进一步评估和研究。
